Lukasz Kuzma/LinkedIn
Feb 16, 2026, 14:44
Lukasz Kuzma: NOAC Monotherapy vs NOAC Plus Clopidogrel in AF Beyond One Year After DES
Lukasz Kuzma, Research Professor at University of Liverpool, shared a post on X about a recent article he and his colleague co-authored, adding:
“In our NEJM editorial with ESC Stroke Chair, we highlight the first RCT in AF more than 1 year after DES showing that NOAC monotherapy was not noninferior and statistically superior to NOAC plus clopidogrel for net adverse clinical events also with less bleeding.”
Title: Thromboprophylaxis for Atrial Fibrillation in Patients with Drug-Eluting Stents
Authors: Gregory Y.H. Lip and Lukasz Kuzma
Read the Full Article on The New England Journal of Medicine.
Stay updated with Hemostasis Today.
-
Mar 6, 2026, 15:18Claudio Laudani: Efficacy and Safety of Colchicine for Secondary Prevention in Coronary Artery Disease
-
Mar 6, 2026, 15:09Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis
-
Mar 6, 2026, 14:56Women’s Health at the Center of the 2025–2027 Global Public Affairs Agenda – ISTH
-
Mar 6, 2026, 14:44Haroun Gajraj: A Must-Have Atlas for Venous Duplex and Phlebology
-
Mar 6, 2026, 14:35Selma Turkovic: Announcing the New Date for the WBIT Webinar
-
Mar 6, 2026, 14:33Caitlin Raymond: Why Transfusion Medicine Should Be Looped in Early in Transfusion Reactions
-
Mar 6, 2026, 14:28Peter Kouides: Why Raising the Ferritin Cutoff in Women Matters
-
Mar 6, 2026, 12:45Gajendra Singh Sandhu: Essential Brain Health Tips to Prevent Stroke
-
Mar 6, 2026, 12:41Jacqui McCallum: A Call to Action from the WSO 2025 Scientific Statement on Sex and Gender Differences in Stroke